

Technology/ Title	Oral STING inhibitor for autoimmune disease therapy	
Subtitle		
Technology Type	<input checked="" type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
Contact Person	Name: Cindy Hsieh	Title: Manager
	Telephone(work): +886-37246166-33209	
	Email:	
Link		
Technology Description	<ul style="list-style-type: none"> • The oral STING inhibitor exhibits high bioavailability across multiple administration routes, including oral, intravenous, and subcutaneous delivery. • The compound shows superior potency, demonstrating more than 20-fold enhancement compared to H-151 in human cell assays. • Oral administration of this inhibitor has proven effective <i>in vivo</i>, successfully ameliorating heart and lung inflammation in the <i>Trex1^{-/-}</i> autoimmune mouse model. <p>Potential disease indications include: chronic autoimmune syndromes, enhanced type-I interferon responses during acute inflammation, neuroinflammatory diseases, chronic bowel disease, and chronic kidney disease.</p>	
Intellectual Property	A US provisional composition-of-matter patent application will be filed in 2026.	
Key Publications	None.	
Business Opportunity	Collaboration or technology transfer.	

